Active Filter(s):
Details:
The Company intends to use the net proceeds to fund the Company's research and development and commercialization activities, including SGX302 (hypericin sodium), a photodynamic light therapy for psoriasis treatment.
Lead Product(s): Hypericin Sodium
Therapeutic Area: Dermatology Product Name: SGX302
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Alliance Global Partners
Deal Size: $4.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 18, 2024
Details:
HyBryte (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light, it demonstrated significant anti-proliferative effects on activated normal human lymphoid cells and inhibited growth of malignant T-cells isolated from CTCL patients.
Lead Product(s): Hypericin Sodium
Therapeutic Area: Oncology Product Name: HyBryte
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2023
Details:
HyBryte (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light, it demonstrated significant anti-proliferative effects on activated normal human lymphoid cells and inhibited growth of malignant T-cells isolated from CTCL patients.
Lead Product(s): Hypericin Sodium
Therapeutic Area: Oncology Product Name: HyBryte
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2023
Details:
Soligenix intends to use the proceeds for commercialization of HyBryte™ (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
Lead Product(s): Hypericin Sodium
Therapeutic Area: Oncology Product Name: HyBryte
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Alliance Global Partners
Deal Size: $8.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 09, 2023
Details:
HyBryte™ (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
Lead Product(s): Hypericin Sodium
Therapeutic Area: Oncology Product Name: HyBryte
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 24, 2023
Details:
HyBryte™ (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
Lead Product(s): Hypericin Sodium
Therapeutic Area: Oncology Product Name: HyBryte
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2023
Details:
The active ingredient in HyBryte is synthetic hypericin, a potent photosensitizer that is topically applied to skin lesions that is taken up by the malignant T-cells, and then activated by visible light approximately 24 hours later.
Lead Product(s): Hypericin Sodium
Therapeutic Area: Oncology Product Name: HyBryte
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2023